Moneycontrol PRO
HomeNewsBusinessHer father's daughter: Avani Singh focuses on the low-cost model of Ajay Singh's SpiceJet to disrupt COVID-19 testing market

Her father's daughter: Avani Singh focuses on the low-cost model of Ajay Singh's SpiceJet to disrupt COVID-19 testing market

Avani, daughter of SpiceJet Chairman & MD Ajay Singh, is the CEO of SpiceHealth

December 18, 2020 / 20:38 IST
SpiceHealth CEO Avani SIngh is the daughter of SpiceJet Chairman and MD Ajay SIngh.
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Sniff an opportunity, quickly start off operations and ensure a low-cost operation. The SpiceJet stamp is unmissable.

    Since it began operations in end-November, SpiceHealth has already set up five labs in Delhi that provide RT-PCR test, starting from Rs 499, to detect COVID-19. The company is now gearing up to add nearly one lab a day with a target to hit 100 by January 2021. It has hired up to 150 technicians, and is holding open door interviews daily to recruit more, and is simultaneously training them in batches.

    The tests are just a start. As soon as COVID-19 vaccines become available, SpiceHealth will use this network of labs to administer the vaccine. To do so, it will work together with SpiceJet's cargo unit SpiceXpress, which has been in the thick of things. The airline, which plans to transport vaccines, has tied up with companies that will have a fleet of refrigerated trucks on the ground. And now, SpiceHealth will provide the last-mile connectivity in this whole network.

    Listen | Will 2021 be a year of recovery for the pharma, auto, and banking sectors?

    SpiceHealth is not a SpiceJet venture, but is led by Avani Singh, daughter of Ajay Singh, the airline's Chairman and Managing Director. The family has founded the company with its own capital.

    COVID-19 Vaccine

    Frequently Asked Questions

    View more
    How does a vaccine work?

    A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

    How many types of vaccines are there?

    There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

    What does it take to develop a vaccine of this kind?

    Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

    View more
    Show

    "The idea has been to keep the cost low, and not compromise on quality," said Avani in a conversation with Moneycontrol. "We have a partner who manufactures the kit, and right from setting up the labs to procuring other equipment, we have kept the cost in mind," added the 24 year-old, who returned from the US in 2019 with a master's degree from Stanford University, and a flying licence.

    While she eventually wants to join the aviation business, in which she has interned in the past, Avani started off her career as a Business Analyst at Mckinsey. "It was in the middle of the (COVID-19) pandemic and working from home, the conversations were about the surging number of cases in Delhi, and the limitations in testing," said the second generation entrepreneur on how the idea struck.

    The idea looked like a good business when the prospective business partner, the Delhi-based genomics company GeneStore, said the tests can be offered at a much lower price point. In Delhi, said Avani, the prevailing market price was Rs 2,400 a test.

    The SpiceHealth CEO said the company has already "made a difference", with the competition now forced to lower its prices. Recognition has also come instantly, and from an industry stalwart. Kiran Mazumdar Shaw, Executive Chairperson of Biocon, tweeted on December 11:

    "Kudos to Avani Singh for launching low-cost and efficient mobile laboratories, certified by the ICMR (Indian Council of Medical Research) and NABL, which conducts more than 3,000 #COVID19 RT-PCR tests per day at an affordable cost of Rs 499."

    Leveraging support

    The start has been promising, but has also brought in scrutiny. "It is a private venture, but seems to be aligned closely with SpiceJet, a listed entity," said a senior industry executive from the aviation industry.

    Avani agreed. "I don’t think I could have done it myself, without leveraging SpiceJet. We have worked closely with SpiceJet," she said. The help has come in the form of setting up SpiceHealth's IT systems and logistics. "SpiceHealth is slowly building up so that our operations can be completely independent," she said.

    She also underlined the role played by her father. "He is the family mentor. I can bounce ideas off him. He is involved in SpiceHealth and ensures smooth functioning at his level," said the daughter.

    Their camaraderie was visible at the launch of SpiceHealth's first lab that was inaugurated by Union Home Minister Amit Shah. The first lab is based in the ICMR's facility, and SpiceHealth will continue to tap the government-owned institute's facilities across the country to set up more units.

    Apart from tapping his own network to ensure success, there is no doubt that the senior Singh also sees SpiceHealth as an opportunity to groom Avani, who has been meeting government officials, bureaucrats, scientists and also the karigars.

    The Singh family has put in "Rs 5 crore to Rs 10 crore" in the venture. "We have started generating cash. The five labs conduct 10-15,000 tests a day each. We hope to be self-sufficient as soon as possible," said Avani.

    From Delhi, SpiceHealth will expand to Haryana and Uttar Pradesh. "We hope to expand across the country," she said. After RT-PCR tests and vaccines, the CEO wants to tap opportunities in genome sequencing.

    And SpiceJet? "I retain my interest in aviation.  I do see myself eventually being involved in SpiceJet, but would like to focus on SpiceHealth right now, and build it up," she added.

    Prince Mathews Thomas
    Prince Mathews Thomas heads the corporate bureau of Moneycontrol. He has been covering the business world for 16 years, having worked in The Hindu Business Line, Forbes India, Dow Jones Newswires, The Economic Times, Business Standard and The Week. A Chevening scholar, Prince has also authored The Consolidators, a book on second generation entrepreneurs.
    first published: Dec 18, 2020 03:24 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseOutskill Genai